effect of oral NAC in hemodialysis patients

The effect of oral N-acetyl cystein on inflammatory markers in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016111529812N2

Enrollment

Registered

2016-12-14

Start date

2014-03-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephropathy. Extracorporeal dialysis

Interventions

intervention(NAC, 600 mg, twice daily, for two months).

Treatment - Drugs

intervention(NAC, 600 mg, twice daily, for two months)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion critera: patients undergone hemodialysis that received hemodialysis for more than 3 month with 3 sessions per week. Exclusion criteria: Patients undergone hemodialysis with venous catheter; symptoms of active infection in one month before starting the study and during the study; rising liver enzymes(ALT and AST); blood transfusion during the study; collagen vascular diseases were the etiology of end stage renal disease; age lesser than 18 –year- old, use of corticosteroid and immunosuppressive drugs; history of myocardial infarction or stroke in 3 month before starting the study; history of intolerance or allergy to NAC.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hs-CRP. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;MDA. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: µmol/dl.;Albomin. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Cholesterol. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Triglycerides. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Hb-A1C. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Calcium. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Phosphorus. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.	—

Measure

Time frame

Hs-CRP. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;MDA. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: µmol/dl.;Albomin. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Cholesterol. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Triglycerides. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Hb-A1C. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: g/dl.;Calcium. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.;Phosphorus. Timepoint: At baseline and Two months after the initiation of trial. Method of measurement: Mg/dl.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Najafee

Nephrology Department, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

farzaneh najafee@yahoo.com+98 35 3822 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026